Save the Date Alliance for Cancer Gene Therapy Award Gala Momentum: 15 Years of Innovative Leadership April 19, 2017 The Harvard Club of New York … Read More
Time Magazine’s year-end “Person of the Year” special issue features the scientists behind CRISPR including ACGT Research Fellow and Scientific Advisory Council member, Dr. Carl June. Read More
The 21st Century Cures Act, which would provide $4.8 billion in new funding for biomedical research, passed both the House of Representatives and the Senate with strong bipartisan support. ‘Cures’ includes $1.8 billion in funding to the Cancer Moonshot initiative. Another nearly $3 billion will go toward the Precision Medicine and BRAIN initiatives. Read More
In 2012, Bob Levis, an Allentown, Pennsylvania resident, believed he had come to the end of his life. Diagnosed in 2002 with chronic lymphocytic leukemia, … Read More
“They took my cancer cells and irradiated them, and then injected them back into my body so my immune system would kick in,” Morrow said. Read More
I am an almost five year survivor of Stage IV NSCLC, adenocarcinoma. I attribute this amazing achievement to the grace of God, aggressive treatment and a “no stone left unturned” attitude. This attitude led me years ago to ACGT and the pioneering work of people like Dr. Jack Roth. Read More
Dr. Stephen Eck, Member of Alliance for Cancer Gene Therapy’s Scientific Advisory Council, talks about the importance of personalized therapies for cancer. “Historically, we’ve tried … Read More
Dr. Michael Lotze, Member of Alliance for Cancer Gene Therapy’s Scientific Advisory Council speaks about progress in the fight against cancer he has witnessed during his … Read More
2015 – 2016 ACGT Young Investigator, Yvonne Chen, MS, PhD, speaks about using engineered T-cells to cure leukemia in this video from May 2016. Great progress … Read More
The mission of ACGT is to seek out and support revolutionary scientific research into the causes, treatment and prevention of all types of cancer using cells and genes as medicine.
Cell and gene therapies are destroying tumors every day in the laboratory and in human trials, targeting only the cancer with few side effects to healthy tissue. ACGT’s rigorous grant review process, under the guidance of a preeminent Scientific Advisory Council, have resulted in some of the most successful breakthroughs in the history of cancer treatments and led to many patients in complete remission.
100% of our funding supports innovation and translational science that is proving again and again to offer better treatment options than the traditional therapies of chemotherapy, surgery and radiation. Every donation brings us closer to saving lives and changing the way we treat cancer forever.